<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055650</url>
  </required_header>
  <id_info>
    <org_study_id>2020-01</org_study_id>
    <nct_id>NCT03055650</nct_id>
  </id_info>
  <brief_title>iLux Treatment for Meibomian Gland Dysfunction (MGD)</brief_title>
  <official_title>iLux Treatment for Meibomian Gland Dysfunction (MGD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tear Film Innovations, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tear Film Innovations, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess changes in meibomian gland function and evaporative dry eye symptoms after treatment
      with the iLux device.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2015</start_date>
  <completion_date type="Actual">February 18, 2016</completion_date>
  <primary_completion_date type="Actual">February 18, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in meibomian gland score between baseline and final follow-up</measure>
    <time_frame>30 days</time_frame>
    <description>Score for 15 lower eyelid meibomian glands in the nasal, medial, and temporal regions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Tear Break-Up Time between baseline and final follow-up</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of discomfort/pain</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of ocular surface staining</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of significant changes in keratometry</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of significant changes in manifest refraction</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of significant changes in BSCVA</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of significant changes in intraocular pressure</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Standard Patient Evaluation of Eye Dryness score</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ocular Surface Disease Index</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>iLux 2020 System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meibomian Gland Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iLux 2020 System</intervention_name>
    <description>Heating and compression to express clogged meibomian glands</description>
    <arm_group_label>iLux 2020 System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years and older of any gender or race

          2. Provision of written informed consent prior to study participation

          3. Willingness and ability to return for all study visits

          4. A positive history of self-reported dry eye symptoms for three months prior to the
             study using the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire, and
             a score of &gt; 6.

          5. Need for regular use of artificial tears, lubricants, or rewetting drops in both eyes

          6. Evidence of meibomian gland (MG) obstruction, based on a total meibomian gland
             secretion score of &lt; 12 out of a maximum score of 45, for 15 glands (5 nasal, 5
             medial, 5 temporal) of the lower eyelid of each eye. Glands expressed &amp; graded from 0
             to 3 (0 = no secretion, 1 = inspissated, 2 = cloudy, 3 = clear liquid).

        Exclusion Criteria:

          1. History of ocular surgery including intraocular, oculo-plastic, corneal or refractive
             surgery within 1 year

          2. Ocular trauma or herpetic keratitis within the previous 3 months

          3. Cicatricial lid margin disease identified via slit lamp examination, including
             pemphigoid, symblepharon, etc.

          4. Active ocular infection (e.g., viral, bacterial, mycobacterial, protozoan, or fungal
             infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac, or eyelids
             including a hordeolum or stye)

          5. Active ocular inflammation or history of chronic, recurrent ocular inflammation within
             prior 3 months (e.g. retinitis, macular inflammation, choroiditis, uveitis, iritis,
             scleritis, episcleritis, keratitis)

          6. Ocular surface abnormality that may compromise corneal integrity (e.g., prior chemical
             burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal
             fluorescein staining, or map dot fingerprint dystrophy

          7. Lid surface abnormalities (e.g., entropion, ectropion, tumor, edema, blepharospasm,
             lagophthalmos, severe trichiasis, severe ptosis) that affect lid function in either
             eye

          8. Anterior blepharitis (staphylococcal, demodex or seborrheic grade 3 or 4)

          9. Ocular trauma, chemical burns, or limbal stem cell deficiency

         10. Systemic disease conditions that cause dry eye (e.g., Stevens-Johnson syndrome,
             vitamin A deficiency, rheumatoid arthritis, Wegener's granulomatosis, sarcoidosis,
             leukemia, Riley-Day syndrome, systemic lupus erythematosus, Sjogren's syndrome)

         11. Women who are pregnant, nursing, or not utilizing adequate birth control measures

         12. Individuals who have either changed the dosing of systemic or ophthalmic medication
             within the past 30 days prior to screening or who are unable or unwilling to remain on
             a stable dosing regimen for the duration of the study

         13. Individuals using isotretinoin (Accutane) within 1 year, cyclosporine-A (Restasis)
             within 2 months, or topical medications other than non-preserved artificial tears
             within 2 weeks.

         14. Individuals using another investigational device or agent within 30 days of study
             participation

         15. Contact lens wearers or individuals who have worn contact lenses in the last 30 days
             or anticipate wearing contact lenses during this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Encinitas Optometry</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92924</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gordon Schanzlin</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Total Vision Care Advance Optometry</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>February 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

